Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug discovery company Sirona Biochem has started the next stage of development for its anti-aging compound library.
Subscribe to our email newsletter
The company’s French subsidiary TFChem has now moved into the next phase of the agreement with France-based contract research organization (CRO) Biogalenys to carry out the trials.
Funding for the project is provided by the French public investment bank, Bpifrance, and the district of Haute Normandie.
As part of the deal, Biogalenys will work with the team of scientists at TFChem to develop the studies on the anti-aging technology.
The research will provide preclinical data supporting multiple targeted applications using new in vitro tests with changing stress conditions and cell types.
The company said that the aim of the project is to both validate the compounds as well as to satisfy the standard cohort of cosmetic safety trials.
Data secured from these trials will be used to determine the optimal commercial applications and joint venture partners.
Sirona Biochem CEO Dr Howard Verrico said: "Our two companies previously worked together successfully on the skin lightening technology and have maintained an excellent relationship of shared knowledge.
"The research on these anti-aging compounds is exciting from both scientific discovery and commercial opportunity prospectus."